Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 12 , ISSUE 3 ( July-September, 2023 ) > List of Articles


Paradigm Shift in Chronic Obstructive Pulmonary Disease Management: Global Initiative for Chronic Obstructive Lung Disease 2023

Anuj K Pandey, Surya Kant, Ajay K Verma

Citation Information : Pandey AK, Kant S, Verma AK. Paradigm Shift in Chronic Obstructive Pulmonary Disease Management: Global Initiative for Chronic Obstructive Lung Disease 2023. Indian J Respir Care 2023; 12 (3):211-213.

DOI: 10.5005/jp-journals-11010-1060

License: CC BY-NC-SA 4.0

Published Online: 30-10-2023

Copyright Statement:  Copyright © 2023; The Author(s).


PDF Share
  1. The Global Strategy for. Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2023 report). (assessed November 2022).
  2. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med 2022;206(11):1317–1325. DOI: 10.1164/rccm.202204-0671PP
  3. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a lancet commission. Lancet 2022;400(10356):921–972. DOI: 10.1016/S0140-6736(22)01273-9
  4. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022;10(5):447–458. DOI: 10.1016/S2213-2600(21)00511-7
  5. World Health Organization. Projections of mortality and causes of death, 2016 and 2060, online information available here: [accessed October 2022].
  6. Agusti A, Melen E, DeMeo DL, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med 2022;10(5):512–524. DOI: 10.1016/S2213-2600(21)00555-5
  7. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005;365(9478):2225–2236. DOI: 10.1016/S0140-6736(05)66781-5
  8. Han MK, Agusti A, Celli BR, et al. From GOLD 0 to pre-COPD. Am J Respir Crit Care Med 2021;203(4):414–423. DOI: 10.1164/rccm.202008-3328PP
  9. Pandey AK, Verma AK, Kant S, et al. The relationship between clinical phenotypes and gold groups/stages in patients with chronic obstructive pulmonary disease. Cureus 2022;14(12):e32116. DOI: 10.7759/cureus.32116
  10. Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J 2007;16(4): 207–214. DOI: 10.3132/pcrj.2007.00034
  11. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume ct screening in a randomized trial. N Engl J Med 2020;382(6):503–513. DOI: 10.1056/NEJMoa1911793
  12. Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med 2021;204(11):1251–1258. DOI: 10.1164/rccm.202108-1819PP
  13. Pandey AK, Singh S, Verma AK, et al. Management strategies of COPD during the COVID-19 pandemic. TANAFFOS (Respiration) RSPR-2205-1217(Accepted).
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.